Fabio Salvatore Macaluso1, Walter Fries2, Antonio Carlo Privitera3, Maria Cappello4, Sebastiano Siringo5, Gaetano Inserra6, Antonio Magnano7, Roberto Di Mitri8, Filippo Mocciaro8, Nunzio Belluardo9, Giuseppe Scarpulla10, Giovanni Magrì11, Antonino Trovatello12, Antonio Carroccio13, Salvatore Genova14, Carmelo Bertolami15, Roberto Vassallo16, Claudio Romano17, Michele Citrano18, Salvatore Accomando19, Marco Ventimiglia1, Sara Renna1, Rosalba Orlando1, Giulia Rizzuto1, Serena Porcari2, Concetta Ferracane3, Mario Cottone1, Ambrogio Orlando1. 1. Inflammatory Bowel Disease Unit, A.O.O.R. 'Villa Sofia-Cervello', Palermo, Italy. 2. Inflammatory Bowel Disease Unit, A.O.U. Policlinico 'G. Martino', Messina, Italy. 3. Inflammatory Bowel Disease Unit, A.O. 'Cannizzaro', Catania, Italy. 4. Gastroenterology and Hepatology Unit, A.O.U. Policlinico 'G. Giaccone', Palermo, Italy. 5. Gastroenterology Unit, A.R.N.A.S. 'Garibaldi', Catania, Italy. 6. Internal Medicine Unit, A.O.U. Policlinico 'Vittorio Emanuele', Catania, Italy. 7. Gastroenterology Unit, A.O.U. Policlinico 'Vittorio Emanuele', Catania, Italy. 8. Gastroenterology and Endoscopy Unit, A.R.N.A.S. 'Civico Di Cristina Benfratelli', Palermo, Italy. 9. Gastroenterology Unit, A.O. 'Guzzardi', Vittoria, Italy. 10. Gastroenterology Unit, A.O.O.R. 'S. Elia- M. Raimondi', Caltanissetta, Italy. 11. Gastroenterology Unit, A.O. 'Santa Marta e S. Venera', Acireale, Italy. 12. Surgery Unit, A.O. 'Umberto I', Siracusa, Italy. 13. Internal Medicine Unit, A.O. 'Giovanni Paolo II', Sciacca, Italy. 14. Gastroenterology and Endoscopy Unit, A.O. 'S. Antonio Abate', Trapani, Italy. 15. Gastroenterology Unit, A.O.O.R. 'Papardo Piemonte', Messina, Italy. 16. Gastroenterology and Endoscopy Unit, A.O. 'Buccheri La Ferla Fatebenefratelli', Palermo, Italy. 17. Pediatric Gastroenterology Unit, A.O.U. Policlinico 'G. Martino', Messina, Italy. 18. Pediatric Unit, A.O.O.R. 'Villa Sofia-Cervello', Palermo, Italy. 19. Pediatric Unit, A.O.U. Policlinico 'G. Giaccone', Palermo, Italy.
Abstract
BACKGROUND AND AIMS: There is an unmet need to better understand the effectiveness of different biologics in inflammatory bowel diseases. We aimed at performing a multicentre, real-life comparison of the effectiveness of infliximab [IFX] and adalimumab [ADA] in Crohn's disease [CD]. METHODS: Data of consecutive patients with CD treated with IFX and ADA from January 2013 to May 2017 were extracted from the cohort of the Sicilian Network for Inflammatory Bowel Disease. We used propensity score-matching accounting for the main baseline characteristics in TNF-α inhibitor-naïve and non-naïve patients. RESULTS: A total of 632 patients [735 total treatments] were included. Among naïve patients, a clinical benefit [the sum of steroid-free remission plus clinical response] was achieved in 81.8% patients treated with ADA and in 77.6% patients treated with IFX (adjusted odds ratio [OR]: 1.23, 95% CI 0.63-2-44, p = 0.547] at 12 weeks; after 1 year, a clinical benefit was achieved in 69.2% of patients treated with ADA and in 64.5% patients treated with IFX [adjusted OR: 1.10, 95% CI 0.61-1.96, p = 0.766]. Among non-naïve patients, a clinical benefit was achieved in 61.7% of patients treated with ADA and in 68.1% of patients treated with IFX [adjusted OR: 0.72, 95% CI 0.21-2.44, p = 0.600] at 12 weeks; after 1 year, a clinical benefit was achieved in 48.9% of patients treated with ADA and in 40.4% patients treated with IFX [adjusted OR: 1.23, 95% CI 0.54-2.86, p = 0.620]. CONCLUSIONS: In this propensity score-matched comparison of ADA and IFX in CD, both drugs showed high rates of clinical benefit, without significant differences between them.
BACKGROUND AND AIMS: There is an unmet need to better understand the effectiveness of different biologics in inflammatory bowel diseases. We aimed at performing a multicentre, real-life comparison of the effectiveness of infliximab [IFX] and adalimumab [ADA] in Crohn's disease [CD]. METHODS: Data of consecutive patients with CD treated with IFX and ADA from January 2013 to May 2017 were extracted from the cohort of the Sicilian Network for Inflammatory Bowel Disease. We used propensity score-matching accounting for the main baseline characteristics in TNF-α inhibitor-naïve and non-naïve patients. RESULTS: A total of 632 patients [735 total treatments] were included. Among naïve patients, a clinical benefit [the sum of steroid-free remission plus clinical response] was achieved in 81.8% patients treated with ADA and in 77.6% patients treated with IFX (adjusted odds ratio [OR]: 1.23, 95% CI 0.63-2-44, p = 0.547] at 12 weeks; after 1 year, a clinical benefit was achieved in 69.2% of patients treated with ADA and in 64.5% patients treated with IFX [adjusted OR: 1.10, 95% CI 0.61-1.96, p = 0.766]. Among non-naïve patients, a clinical benefit was achieved in 61.7% of patients treated with ADA and in 68.1% of patients treated with IFX [adjusted OR: 0.72, 95% CI 0.21-2.44, p = 0.600] at 12 weeks; after 1 year, a clinical benefit was achieved in 48.9% of patients treated with ADA and in 40.4% patients treated with IFX [adjusted OR: 1.23, 95% CI 0.54-2.86, p = 0.620]. CONCLUSIONS: In this propensity score-matched comparison of ADA and IFX in CD, both drugs showed high rates of clinical benefit, without significant differences between them.
Authors: Rebecca Faleiro; Ji Liu; Deshapriya Karunarathne; Aleksandra Edmundson; Clay Winterford; Tam Hong Nguyen; Lisa A Simms; Graham Radford-Smith; Michelle Wykes Journal: Clin Transl Immunology Date: 2019-07-25
Authors: Gustavo Drügg Hahn; Petra Anna Golovics; Panu Wetwittayakhlang; Alex Al Khoury; Talat Bessissow; Peter Laszlo Lakatos Journal: Biomedicines Date: 2022-03-23